Single User License
INR 135860
Site License
INR 271720
Corporate User License
INR 407580

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Non Alcoholic Fatty Liver Disease (NAFLD)-Pipeline Review, H1 2015

Non Alcoholic Fatty Liver Disease (NAFLD)-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Non Alcoholic Fatty Liver Disease (NAFLD)-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Non Alcoholic Fatty Liver Disease (NAFLD)-Pipeline Review, H1 2015', provides an overview of the Non Alcoholic Fatty Liver Disease (NAFLD)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Non Alcoholic Fatty Liver Disease (NAFLD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non Alcoholic Fatty Liver Disease (NAFLD) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Non Alcoholic Fatty Liver Disease (NAFLD)

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Non Alcoholic Fatty Liver Disease (NAFLD) and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Non Alcoholic Fatty Liver Disease (NAFLD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Non Alcoholic Fatty Liver Disease (NAFLD) pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Non Alcoholic Fatty Liver Disease (NAFLD)

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Non Alcoholic Fatty Liver Disease (NAFLD) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Non Alcoholic Fatty Liver Disease (NAFLD) Overview 8

Therapeutics Development 9

Pipeline Products for Non Alcoholic Fatty Liver Disease (NAFLD)-Overview 9

Pipeline Products for Non Alcoholic Fatty Liver Disease (NAFLD)-Comparative Analysis 10

Non Alcoholic Fatty Liver Disease (NAFLD)-Therapeutics under Development by Companies 11

Non Alcoholic Fatty Liver Disease (NAFLD)-Therapeutics under Investigation by Universities/Institutes 13

Non Alcoholic Fatty Liver Disease (NAFLD)-Pipeline Products Glance 14

Late Stage Products 14

Clinical Stage Products 15

Early Stage Products 16

Non Alcoholic Fatty Liver Disease (NAFLD)-Products under Development by Companies 17

Non Alcoholic Fatty Liver Disease (NAFLD)-Products under Investigation by Universities/Institutes 18

Non Alcoholic Fatty Liver Disease (NAFLD)-Companies Involved in Therapeutics Development 19

Conatus Pharmaceuticals Inc. 19

Daewoong Pharmaceutical Co., Ltd. 20

Galmed International Ltd. 21

Kyorin Pharmaceutical Co., Ltd. 22

Metabolic Solutions Development Company, LLC 23

Novartis AG 24

Phenex Pharmaceuticals AG 25

Raptor Pharmaceuticals Corp. 26

TCM Biotech International Corp 27

Tobira Therapeutics, Inc. 28

Verva Pharmaceuticals Limited 29

Zafgen Inc. 30

Non Alcoholic Fatty Liver Disease (NAFLD)-Therapeutics Assessment 31

Assessment by Monotherapy Products 31

Assessment by Target 32

Assessment by Mechanism of Action 35

Assessment by Route of Administration 37

Assessment by Molecule Type 38

Drug Profiles 40

Antisense Oligonucleotides to Target ABHD6 for Gastrointestinal and Metabolic Disorders-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

Aramchol-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

cenicriviroc-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

cysteamine DR-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

DWP-10292-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

emricasan-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

MAT-8800-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

MB-12066-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

methazolamide-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

MN-002-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

MSDC-0602-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

oltipraz-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

pradigastat sodium-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

Px-102-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

Px-103-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

Px-104-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

Small Molecules to Activate AMPK for Fatty Liver Disease-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

TCM-606F-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

VVP-100-X-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

ZGN-839-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

Non Alcoholic Fatty Liver Disease (NAFLD)-Recent Pipeline Updates 66

Non Alcoholic Fatty Liver Disease (NAFLD)-Dormant Projects 80

Non Alcoholic Fatty Liver Disease (NAFLD)-Product Development Milestones 81

Featured News & Press Releases 81

Apr 28, 2014: Galmed Pharmaceuticals Commences Patient Screening for Aramchol Pharmacokinetic and Food Effect Studies 81

Oct 31, 2012: Phenex Pharma Completes Phase I Studies With FXR-Agonist Px-102 81

Appendix 83

Methodology 83

Coverage 83

Secondary Research 83

Primary Research 83

Expert Panel Validation 83

Contact Us 84

Disclaimer 84

List of Tables

Number of Products under Development for Non Alcoholic Fatty Liver Disease (NAFLD), H1 2015 9

Number of Products under Development for Non Alcoholic Fatty Liver Disease (NAFLD)-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 12

Number of Products under Investigation by Universities/Institutes, H1 2015 13

Comparative Analysis by Late Stage Development, H1 2015 14

Comparative Analysis by Clinical Stage Development, H1 2015 15

Comparative Analysis by Early Stage Development, H1 2015 16

Products under Development by Companies, H1 2015 17

Products under Investigation by Universities/Institutes, H1 2015 18

Non Alcoholic Fatty Liver Disease (NAFLD)-Pipeline by Conatus Pharmaceuticals Inc., H1 2015 19

Non Alcoholic Fatty Liver Disease (NAFLD)-Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2015 20

Non Alcoholic Fatty Liver Disease (NAFLD)-Pipeline by Galmed International Ltd., H1 2015 21

Non Alcoholic Fatty Liver Disease (NAFLD)-Pipeline by Kyorin Pharmaceutical Co., Ltd., H1 2015 22

Non Alcoholic Fatty Liver Disease (NAFLD)-Pipeline by Metabolic Solutions Development Company, LLC, H1 2015 23

Non Alcoholic Fatty Liver Disease (NAFLD)-Pipeline by Novartis AG, H1 2015 24

Non Alcoholic Fatty Liver Disease (NAFLD)-Pipeline by Phenex Pharmaceuticals AG, H1 2015 25

Non Alcoholic Fatty Liver Disease (NAFLD)-Pipeline by Raptor Pharmaceuticals Corp., H1 2015 26

Non Alcoholic Fatty Liver Disease (NAFLD)-Pipeline by TCM Biotech International Corp, H1 2015 27

Non Alcoholic Fatty Liver Disease (NAFLD)-Pipeline by Tobira Therapeutics, Inc., H1 2015 28

Non Alcoholic Fatty Liver Disease (NAFLD)-Pipeline by Verva Pharmaceuticals Limited, H1 2015 29

Non Alcoholic Fatty Liver Disease (NAFLD)-Pipeline by Zafgen Inc., H1 2015 30

Assessment by Monotherapy Products, H1 2015 31

Number of Products by Stage and Target, H1 2015 34

Number of Products by Stage and Mechanism of Action, H1 2015 36

Number of Products by Stage and Route of Administration, H1 2015 37

Number of Products by Stage and Molecule Type, H1 2015 39

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics-Recent Pipeline Updates, H1 2015 66

Non Alcoholic Fatty Liver Disease (NAFLD)-Dormant Projects, H1 2015 80

List of Figures

Number of Products under Development for Non Alcoholic Fatty Liver Disease (NAFLD), H1 2015 9

Number of Products under Development for Non Alcoholic Fatty Liver Disease (NAFLD)-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 11

Comparative Analysis by Clinical Stage Development, H1 2015 15

Comparative Analysis by Early Stage Products, H1 2015 16

Assessment by Monotherapy Products, H1 2015 31

Number of Products by Top 10 Targets, H1 2015 32

Number of Products by Stage and Top 10 Targets, H1 2015 33

Number of Products by Top 10 Mechanism of Actions, H1 2015 35

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 36

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 37

Number of Products by Top 10 Molecule Types, H1 2015 38

Number of Products by Stage and Top 10 Molecule Types, H1 2015 39

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Conatus Pharmaceuticals Inc.

Daewoong Pharmaceutical Co., Ltd.

Galmed International Ltd.

Kyorin Pharmaceutical Co., Ltd.

Metabolic Solutions Development Company, LLC

Novartis AG

Phenex Pharmaceuticals AG

Raptor Pharmaceuticals Corp.

TCM Biotech International Corp

Tobira Therapeutics, Inc.

Verva Pharmaceuticals Limited

Zafgen Inc.

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutic Products under Development, Key Players in Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, Non Alcoholic Fatty Liver Disease (NAFLD) Pipeline Overview, Non Alcoholic Fatty Liver Disease (NAFLD) Pipeline, Non Alcoholic Fatty Liver Disease (NAFLD) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com